Email bulletin archive

Archive

November 2014

• News from The Liver Meeting
• Interferon-free treatment: sofosbuvir/ledipasvir
• Decompensated cirrhosis
• HIV and hepatitis C co-infection
• Interferon-free treatment: other regimens for HCV genotype 1
• A single interferon-free treatment for multiple genotypes?
• Interferon-free treatment for genotype 4 infection
• Survival
• AbbVie '3D' interferon-free combination receives scientific approval in European Union
• Hepatitis C treatment factsheets
• Is this your copy of the infohep news bulletin?

October 2014

• Cost and access issues
• Harvoni approved in US
• Petition for improved HCV diagnosis and treatment for people in Europe who use drugs
• Egypt infection control
• Hepatitis C treatment factsheets
• Is this your copy of the infohep news bulletin?

September 2014

• Daclatasvir (Daklinza) approved in the EU
• Universal access to hepatitis C treatment in the EU
• Access to hepatitis C treatment outside the EU and US
• US insurance restrictions and barriers to treatment
• Pricing of sofosbuvir / ledipasvir
• First European Conference on hepatitis C and harm reduction
• Hepatitis C treatment factsheets
• Is this your copy of the infohep news bulletin?

July 2014

• Daclatasvir recommended for European approval
• Hepatitis C treatment during opioid substitution therapy
• Hepatitis C treatment for people with HIV and hepatitis C co-infection
• Hepatitis C treatment factsheets
• Customise your hepatitis information
• Is this your copy of the infohep news bulletin?

June 2014

• Disease and healthcare utilisation burden without treatment
• Recent European decisions on reimbursement for sofosbuvir treatment of hepatitis C
• Merck buys Idenix to improve its hepatitis C portfolio
• BMS aims to test four-week treatment course for HCV
• Faldaprevir discontinued
• Achillion development plans
• Getting ready for World Hepatitis Day?
• New! Hepatitis C treatment factsheets
• New! Customise your hepatitis information
• Is this your copy of the infohep news bulletin?

May 2014

• Simeprevir marketing approval
• Hepatitis B screening recommendations
• Sofosbuvir for treatment of genotype 4 hepatitis C
• Sofosbuvir for treatment of post-transplant hepatitis C recurrence
• US health insurers question the price of sofosbuvir
• New! Hepatitis C treatment factsheets
• New! Customise your hepatitis information
• Is this your copy of the infohep news bulletin?

April 2014

• New European treatment guidelines for hepatitis C
• World Health Organization issues treatment guidelines for hepatitis C
• Access
• Hepatitis C treatment news from the International Liver Congress
• Prevention of hepatitis C infection
• Hepatitis B treatment
• Hepatitis delta treatment
• New! Hepatitis C treatment factsheets
• New! Customise your hepatitis information
• Is this your copy of the infohep news bulletin?

March 2014

• Shorter treatment is possible for hard-to-treat patients
• Simeprevir – new HCV protease inhibitor
• AbbVie '3D' combination highly potent treatment for genotype 1b infection
• HIV co-infection
• Other interferon-free combinations on the way
• European policy
• Cost of treatment
• Access to treatment
• Egypt negotiates 99% discount on sofosbuvir price
• Forthcoming events
• Is this your copy of the infohep news bulletin?

February 2014

• Access to hepatitis C treatment
• Treat or wait?
• AbbVie completes interferon-free trials programme
• Gilead seeks approval for ledipasvir/sofosbuvir combination tablet
• Hepatitis C stroke risk
• Hepatitis B screening guidelines in US
• Is this your copy of the infohep news bulletin?

January 2014

• New US hepatitis C treatment guidelines
• New European hepatitis C treatment guidelines
• Sofosbuvir approval in European Union
• Sofosbuvir/ledipasvir results
• Daclatasvir filing in European Union
• Other new drugs news
• Is your organisation listed in the infohep services database?